ĀÜĄņĀŅĀ×

Otto is an Approach-specific Scientist of ORI Capital. Ottoā€™s primary responsibilities include conducting science and technology due diligence as well as certain post investment portfolio activities. Prior to joining ORI Capital, Otto worked as a Business Analyst in the healthcare strategy consulting team of Deloitte Consulting. During his academic career, Otto's major research focuses were cancer epigenetics and cancer immunology. Otto received a BSc in Life Science and a PhD from the Chinese University of Hong Kong.